CRISPR-based gene editing shows promise in treating rare form of blindness

FHS
May 6, 2024
6:43 pm

About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine.

Optum’s biosimilar business to exclude brand-name Stelara, Humira in 2025

Optum Rx is moving into the biosimilar business with a company it’s calling Nuvaila, and it’s starting out with biosimilars to AbbVie’s blockbuster rheumatoid arthritis

September 11, 2024

Augmedics names Paul Ziegler as CEO

Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. Name: Paul Ziegler Current role: CEO and

December 13, 2024

Jerry Teixeira – Why Do Bodyweight Strength Training Exercises – BioHackers Lab

The man behind the Bodyweight Strength Training YouTube channel, Jerry Teixeira (JT), is today’s guest interview. JT talks to us about how you can get

February 25, 2020

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.